Cases
OHR Pharmaceutical, Inc. (OHRP)
Securities Class Action
Overview
Overview
- Date:
- 1/4/2019
- Company Name:
- Ohr Pharmaceutical, Inc.
- Stock Symbol:
- OHRP
- Company Name - Buyer:
- Omega Healthcare Investors, Inc.
- Stock Symbol - Buyer:
- OHI
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/3/2019
NEW YORK, January 4, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) on behalf of stockholders concerning the proposed acquisition of the company by Omega Healthcare Investors, Inc. (NYSE: OHI).
Pursuant to the proposed transaction, announced on January 3, 2019, OHR stockholders will receive one share of NeuBase for each share of OHR common stock owned. The investigation focuses on whether OHR and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own OHR shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on January 3, 2019, OHR stockholders will receive one share of NeuBase for each share of OHR common stock owned. The investigation focuses on whether OHR and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own OHR shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.